American Century Companies Inc. Has $124.78 Million Stock Holdings in Hologic, Inc. $HOLX

American Century Companies Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.9% in the third quarter, Holdings Channel reports. The firm owned 1,848,892 shares of the medical equipment provider’s stock after purchasing an additional 196,898 shares during the quarter. American Century Companies Inc.’s holdings in Hologic were worth $124,782,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after buying an additional 3,520 shares during the period. Empowered Funds LLC raised its stake in Hologic by 27.7% during the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after acquiring an additional 3,790 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Hologic by 22.0% during the second quarter. Assetmark Inc. now owns 3,285 shares of the medical equipment provider’s stock valued at $214,000 after acquiring an additional 593 shares during the period. Strs Ohio boosted its stake in shares of Hologic by 2.6% in the 2nd quarter. Strs Ohio now owns 214,332 shares of the medical equipment provider’s stock valued at $13,966,000 after purchasing an additional 5,332 shares in the last quarter. Finally, South Dakota Investment Council grew its holdings in shares of Hologic by 68.0% in the 2nd quarter. South Dakota Investment Council now owns 12,600 shares of the medical equipment provider’s stock worth $821,000 after purchasing an additional 5,100 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Morgan Stanley lifted their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Friday, November 21st. Finally, Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their target price for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Up 0.2%

Shares of NASDAQ:HOLX opened at $75.36 on Monday. The company’s 50-day moving average price is $74.95 and its two-hundred day moving average price is $72.16. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.49. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The stock has a market capitalization of $16.82 billion, a PE ratio of 31.40, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 EPS. On average, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.